{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:16:13Z","timestamp":1789020973413,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T00:00:00Z","timestamp":1401840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s40261-014-0203-4","type":"journal-article","created":{"date-parts":[[2014,6,3]],"date-time":"2014-06-03T01:57:36Z","timestamp":1401760656000},"page":"521-528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Preservative-Free Latanoprost Eye Drops in Patients with Primary Open-Angle Glaucoma\/Ocular Hypertension"],"prefix":"10.1007","volume":"34","author":[{"given":"Mark","family":"Sanford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,4]]},"reference":[{"issue":"4","key":"203_CR1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-158-4-201302190-00008","volume":"158","author":"MV Boland","year":"2013","unstructured":"Boland MV, Ervin A-M, Friedman DS, et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2013;158(4):271\u20139.","journal-title":"Ann Intern Med"},{"issue":"8","key":"203_CR2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00002512-200320080-00005","volume":"20","author":"CM Perry","year":"2003","unstructured":"Perry CM, McGavin JK, Culy CR, et al. Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging. 2003;20(8):597\u2013630.","journal-title":"Drugs Aging"},{"key":"203_CR3","unstructured":"American Academy of Ophthalmology. Primary open-angle glaucoma preferred practice pattern. 2010. http:\/\/one.aao.org\/preferred-practice-pattern\/primary-openangle-glaucoma-ppp\u2013october-2010. Accessed 16 Apr 2014."},{"key":"203_CR4","unstructured":"European Glaucoma Society. Terminology and guidelines for glaucoma (3rd Edition). 2008. http:\/\/www.eugs.org\/eng\/EGS_guidelines.asp . Accessed 16 Apr 2014."},{"key":"203_CR5","unstructured":"National Institute for Health and Care Excellence. Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension (NICE clinical guideline 85). 2009. http:\/\/www.nice.org.uk\/nicemedia\/live\/12145\/43839\/43839.pdf . Accessed 16 Apr 2014."},{"key":"203_CR6","unstructured":"American Academy of Ophthalmology. Primary open-angle glaucoma summary benchmark. 2013. http:\/\/one.aao.org\/summary-benchmark-detail\/primary-openangle-glaucoma-summary-benchmark\u2013octo. Accessed 16 Apr 2014."},{"issue":"3","key":"203_CR7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/bjo.2007.135111","volume":"93","author":"F Honrubia","year":"2009","unstructured":"Honrubia F, Garcia-Sanchez J, Polo V, et al. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol. 2009;93(3):316\u201321.","journal-title":"Br J Ophthalmol"},{"key":"203_CR8","first-page":"261","volume":"4","author":"A Arias","year":"2010","unstructured":"Arias A, Schargel K, Ussa F, et al. Patient persistence with first-line antiglaucomatous monotherapy. Clin Ophthalmol. 2010;4:261\u20137.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"203_CR9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312\u201334.","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"203_CR10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bjo.86.4.418","volume":"86","author":"PJ Pisella","year":"2002","unstructured":"Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418\u201323.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"203_CR11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/112067210701700311","volume":"17","author":"N Jaenen","year":"2007","unstructured":"Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17(3):341\u20139.","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"203_CR12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/ICU.0b013e32835c8aba","volume":"24","author":"Z Anwar","year":"2013","unstructured":"Anwar Z, Wellik SR, Galora A. Glaucoma therapy and ocular surface disease: current literature and recommendations. Curr Opin Ophthalmol. 2013;24(2):136\u201343.","journal-title":"Curr Opin Ophthalmol"},{"key":"203_CR13","unstructured":"Spectrum Thea Pharmaceuticals, Ltd. Monoprost 50 micrograms\/ml eyedrops in a single-dose container: UK summary of product characteristics. http:\/\/www.medicines.org.uk\/emc\/medicine\/27436\/SPC\/MONOPROST+latanoprost+50+mcg+ml+eye+drops%2c+solution+in+single-dose+container . Accessed 6 May 2014."},{"issue":"4","key":"203_CR14","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.exer.2008.12.012","volume":"88","author":"A Alm","year":"2009","unstructured":"Alm A, Nilsson SF. Uveoscleral outflow\u2014a review. Exp Eye Res. 2009;88(4):760\u20138.","journal-title":"Exp Eye Res"},{"issue":"6","key":"203_CR15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/bjo.2010.189449","volume":"95","author":"H Liang","year":"2011","unstructured":"Liang H, Pauly A, Riancho L, et al. Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. Br J Ophthalmol. 2011;95(6):869\u201375.","journal-title":"Br J Ophthalmol"},{"issue":"13","key":"203_CR16","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.1167\/iovs.12-10766","volume":"53","author":"A Pauly","year":"2012","unstructured":"Pauly A, Roubeix C, Liang H, et al. In vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulation. Invest Ophthalmol Vis Sci. 2012;53(13):8172\u201380.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"203_CR17","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/IJG.0b013e31824d8d7c","volume":"22","author":"K Inoue","year":"2013","unstructured":"Inoue K, Shiokawa M, Wakakura M, et al. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma. 2013;22(8):626\u201331.","journal-title":"J Glaucoma"},{"issue":"2","key":"203_CR18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10384-012-0219-3","volume":"57","author":"R Sakata","year":"2013","unstructured":"Sakata R, Shirato S, Miyata K, et al. Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost. Jpn J Ophthalmol. 2013;57(2):179\u201384.","journal-title":"Jpn J Ophthalmol"},{"issue":"6","key":"203_CR19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s10384-011-0075-6","volume":"55","author":"M Aihara","year":"2011","unstructured":"Aihara M, Shirato S, Sakata R. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Jpn J Ophthalmol. 2011;55(6):600\u20134.","journal-title":"Jpn J Ophthalmol"},{"issue":"6","key":"203_CR20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1089\/jop.2009.0049","volume":"25","author":"S Hariharan","year":"2009","unstructured":"Hariharan S, Minocha M, Mishra GP, et al. Interaction of ocular hypotensive agents (PGF2 analogs - bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea. J Ocul Pharmacol Ther. 2009;25(6):487\u201397.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"Suppl 1","key":"203_CR21","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0039-6257(02)00302-8","volume":"47","author":"B Sjoquist","year":"2002","unstructured":"Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47(Suppl 1):S6\u201312.","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"203_CR22","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/bjophthalmol-2012-302121","volume":"97","author":"J-F Rouland","year":"2013","unstructured":"Rouland J-F, Traverso CE, Stalmans I, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013;97(2):196\u2013200.","journal-title":"Br J Ophthalmol"},{"key":"203_CR23","author":"M Cucherat","year":"2013","unstructured":"Cucherat M, Stalmans I, Rouland JF. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted indirect comparison meta-analysis of randomized clinical trials. J Glaucoma. 2013;. doi: 10.1097\/IJG.0b013e3182a075e6 .","journal-title":"J Glaucoma"},{"key":"203_CR24","unstructured":"PRISMA, transparent reporting of systematic reviews and meta-analyses. The PRISMA statement. http:\/\/prisma-statement.org\/statement.htm . Accessed 16 Apr 2014."},{"issue":"6","key":"203_CR25","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analyses of randomized, controlled trials. J Clin Epidemiol. 1997;50(6):683\u201391.","journal-title":"J Clin Epidemiol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0203-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-014-0203-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0203-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T02:44:27Z","timestamp":1565491467000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-014-0203-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,4]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["203"],"URL":"https:\/\/doi.org\/10.1007\/s40261-014-0203-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,4]]}}}